Clinical Trials Logo

Atypical Mycobacterium Infection clinical trials

View clinical trials related to Atypical Mycobacterium Infection.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00004296 Completed - Cystic Fibrosis Clinical Trials

Multicenter Study of Nontuberculous Mycobacteria in Cystic Fibrosis Patients

Start date: September 1995
Phase: N/A
Study type: Observational

OBJECTIVES: I. Determine the prevalence of nontuberculous mycobacteria in sputum cultures from patients with cystic fibrosis. II. Compare the clinical course of patients with negative versus positive cultures.

NCT ID: NCT00001911 Completed - Clinical trials for Atypical Mycobacterium Infection

Interleukin-12 in the Treatment of Severe Nontuberculous Mycobacterial Infections

Start date: July 1999
Phase: Phase 1
Study type: Interventional

This study will test the safety and effectiveness of a drug called interleukin-12 (IL-12) in fighting severe infectious (other than tuberculosis) caused by a group of bacteria called mycobacteria. IL-12 is similar to a substance the body produces naturally to strengthen immune function (infection-fighting ability). It works by stimulating white blood cells to increase production of a chemical called interferon gamma, which can improve or cure mycobacterial infections in some patients. In previous studies, IL-12 has improved immune function against mycobacteria in test tube experiments and in mice. A recent study of three patients with mycobacterial infections treated with the drug showed encouraging results. The drug has also been studied more extensively in patients with cancer, HIV infection and hepatitis C. Patients in this study will receive IL-12 injections under the skin twice a week for one year. They will be taught how to self-administer the drug, but a home care nurse or a physician may also give the injections. The drug dosage will be increased each week to determine the safest and most effective dose for fighting this infection. If intolerable side effects develop at a certain dose, the previous dose level will be used for the next injection. That dose will then be used for the rest of the study, unless unacceptable side effects develop at that level, in which case the dose will again be lowered. Patients will receive an antibiotic against mycobacteria. Physical examinations and blood and urine tests will be done once a month for at least the first year and then every 3 months the following year to evaluate kidney, liver, and immune function. The first evaluation-at the start of the study-is done on an inpatient basis.